„Benign gastric ulcer
„Duodenal ulcer
„Duodenal ulcer and benign gastric ulcer associated with H. pylori infection
„Healing of erosive or ulcerative Gastroesophageal reflux disease (GERD)
„Zollinger-Ellison Syndrome
„Prevention or treatment of NSAIDs-induced ulcers
„Treatment of symptomatic GERD
„Maintenance of healing of erosive or ulcerative GERD

1) Benign gastric ulcer : 20 mg daily in the morning for 8 weeks.
2) Duodenal ulcer : 20 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed.
3) Duodenal ulcer and benign gastric ulcer associated with H. pylori infection: Rabeprol in combination with Amoxicillin and Clarithromycin as a three drug regimen is indicated for the treatment of patients with H. pylori lnfection and duodenal ulcer disease. Rabeprazole offer a faster therapy option than other PPIs, up to 10 to 14 days 20 mg once daily.
4) Healing of erosive or ulcerative Gastroesophageal reflux disease : 20 mg once daily for 4-8 weeks; maintenance 10-20 mg daily; symptomatic treatment in the absence of oesophagitis, 10 mg daily for up to 4 weeks then 10 mg daily when required.
5) Zollinger-Ellison Syndrome : Initially 60 mg once daily adjusted according to response (maximum 120 mg daily); doses above 100 mg daily given in 2 divided doses.
6) Prevention or treatment of NSAIDs-induced ulcers: Rabeprol 20 mg once daily. In patients receiving treatment with NSAIDs.
7) Treatment of symptomatic GERD: The recommended adult oral dose of Rabeprol is 20 mg once daily for 4 weeks. lf symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.
8) Maintenance of healing of erosive or ulcerative GERD: Rabeprol is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative GERD maintenance. Controlled studies do not extend beyond l2 months.
9) Treatment of GERD in Pediatric Patients 1 to 11 Years of Age: The recommended dosage for pediatric patients 1 to 11 years of age by body weight is:
· Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if inadequate response.
· 15 kg or more: 10 mg once daily for up to 12 weeks.

Rabeprazole is mainly metabolized by nonenzymatic pathway. Studies in healthy subjects have shown that Rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP-450 system, such as warfarin and theophylline given as single oral doses, diazepam as a single intravenous dose, and phenytoin given as a single intravenous dose.

Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, other PPIs or to any component of the formulation.

In general, Rabeprazole is well-tolerated in both short-term and long-term studies. Rabeprazole may some times cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness.

Rabeprazole Sodium tablet /capsule should not be splited, chewed or crushed.